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  34 
ABSTRACT 35 
 36 
The solid state of adefovir dipivoxil (AD) has been revisited. In the present article we extend the 37 
knowledge about the solid state of this pharmaceutical prodrug. The stability landscape of the 38 
amorphous form with respect to the anhydrous and hydrate crystalline forms has been studied, and the 39 
use of an antiplasticizing agent to increase its Tg is described. The crystal structure of the elusive 40 
anhydrous form I has been determined from laboratory powder X-ray diffraction data by means of direct 41 
space methods using the computing program FOX. In addition, three new isostructural solvates of AD 42 
(methanol, ethylenglycol, and methylethylketone) have been discovered and structurally characterized 43 






  50 
1. INTRODUCTION 51 
 52 
The solid state properties of active pharmaceutical ingredients (APIs) are of great importance in the 53 
pharmaceutical field because the delivery of an API with the most suitable solubility, bioavailability and 54 
stability profiles depends on which crystal form of the drug is present. Most of the marketed drugs are 55 
polymorphic; thus the knowledge of the factors favoring a particular crystal form can be vital during the 56 
development of a pharmaceutical formulation.1 57 
Adefovir dipivoxil (9-{2-[bis(pivaloyloxymethoxy)- phosphinylmethoxy]ethyl}adenine, AD hereafter) 58 
(Figure 1) is a nucleotide reverse transcriptase inhibitor that exhibits a marked in vivo antiviral activity 59 
against both HIV and HBV,2,3 and it is effective against other several human virus. In particular, AD is 60 
an important drug for the treatment of hepatitis B virus infection.4−6 61 
The relevance of this drug has prompted in the past an intensive solid state research, resulting in a high 62 
number of crystal forms. The AD solid state forms that have been reported in the literature include the 63 
amorphous,7 three anhydrous polymorphs,8−10 a dihydrate,11 two polymorphic monohydrates, 12 a 64 
hemihydrate,13 a methanol solvate,8 a butanolate solvate,14 a novel crystal form with 6.0%−7.5% water 65 
content,15 a dichloromethane hemi solvate and another anhydrous form,16 and several salts and 66 
cocrystals.17 Moreover, different local patents describe other forms.18,19 Although five 67 
multicomponent crystal structures have been described in the literature (a succinic acid cocrystal,20 a 68 
saccharin cocrystal,21 a suberic acid cocrystal,20 a nicotinamide cocrystal,17 and a dihydrate11), the 69 
crystal structure of any anhydrous form remains, so far, elusive. 70 
Hence, with the aim of extending the solid state knowledge of AD we are reporting for the first time the 71 
crystal structure of the anhydrous form I together with three new isostructural solvate forms. Moreover, 72 
the relative stability among the polymorphs and amorphous phases is described, and the use of an 73 
antiplasticizing agent to stabilize the amorphous AD is investigated. 74 
  75 
2. MATERIALS AND METHODS 76 
 77 
2.1. Synthesis of the Different Crystal Forms. 78 
2.1.1. Form I. It was obtained by slow crystallization from a solution of AD in anhydrous MEK, AcOEt, 79 
toluene, heptane, xylene, or MTBE. (mp 98 °C). 80 
2.1.2. Form II. It was obtained from a methodology described in the literature:4 N,N′-dicyclohexyl-4-81 
morpholinecarboxamidine and chloromethyl pivalate were added to a solution of 9-[2-82 
(phosphonomethoxy)ethyl]adenine in anhydrous DMF. After 36 h of stirring at room temperature, the 83 
insolubles were filtered off, and the filtrate was concentrated in vacuo, and it was purified by silica gel 84 
chromatography (mp 78 °C). 85 
2.1.3. Form III. It was obtained by precipitation after the addition of pentane to a solution of AD in 86 
heptane (mp 93 °C). 87 
2.1.4. Form IV. It was obtained by slow crystallization from a solution of 50 mg of AD in THF (mp 80 88 
°C). 89 
2.1.5. Form V. It was obtained by slow crystallization from a solution of 100 mg of AD in 90 
dichloromethane (mp 91 °C).  91 
2.1.6. Dihydrate. It was obtained by crystallization at low temperature from not anhydrous MEK, THF, 92 
MIBK, AcOEt, or H2O (TGA analysis shows a weight loss of 6.9% which corresponds to two 93 
molecules of water). 94 
2.1.7. Methanol Solvate. It was obtained by precipitation of a dissolution of AD in methanol at 0 °C 95 
(TGA analysis shows a weight loss of 6% which suggests a 1:1 stoichiometry). 96 
2.1.8. Ethylenglycol Hemisolvate. It was obtained from precipitation of a dissolution of AD in 97 
ethylenglycol at −10 °C (TGA analysis shows a weight loss of 5.9% which suggests a 2:1 98 
(AD/ethylenglycol) stoichiometry). 99 
2.1.9. Methylethylketone Hemisolvate. It was obtained by evaporation at r.t. of a solution of AD in 100 
MEK (TGA analysis shows a weight loss of 4.7% which suggests a 2:1 (AD:MEK) stoichiometry). 101 
2.1.10. Preparation of 1:3 AD-Copovidone Solid Dispersion. AD (60 mg) and copovidone (180 mg) 102 
were dissolved in 5 mL of dioxane at r.t. The solution was frozen at −40 °C (acetone/CO2), and it was 103 
lyophilized during 2 h until dryness. An amorphous white solid was obtained (Tg 71 °C, 100% yield). 104 
2.2. Methods. 2.2.1. Powder X-ray Diffraction (PXRD). Powder X-ray diffraction patterns were 105 
obtained on a PANalytical X’Pert PRO MPD diffractometer in transmission configuration using Cu Kα1 106 
+ 2 radiation (λ = 1.5418 Å) with a focalizing elliptic mirror, a PIXcel detector working at a maximum 107 
detector’s active length of 3.347°. Capillary geometry has been used with samples placed in glass 108 
capillaries (Lindemman) of 0.5 mm of diameter measuring from 2 to 60° in 2θ, with a step size of 109 
0.026° and a total measuring time of 30 min. Flat geometry has been used for routine samples 110 
sandwiched between low absorbing films (polyester of 3.6 μm of thickness) measuring 2θ/θ scans from 111 
2 to 40° in 2θ with a step size of 0.026° and a measuring time of 76 s per step. Powder X-ray diffraction 112 
pattern of form I was obtained using capillary geometry and soller slit of 0.01 radians. The sample was 113 
placed in a capillary of 0.7 mm and consecutive 2θ scans from 2 to 70° were measured and added. The 114 
total measuring time was 60 h. 115 
2.2.2. Single Crystal X-ray Diffraction. MAR345 diffractometer with an image plate detector was used. 116 
Intensities were collected with graphite monochromatized MoKα radiation (λ = 0.71073 Å) using a 117 
ϕ−scan technique. The structures were solved by direct methods using SHELXS computer program22 118 
and refined by full-matrix least-squares method with SHELX97 computer program. 119 
2.2.3. Differential Scanning Calorimetry (DSC). Differential scanning calorimetry was carried out by 120 
means of a Mettler-Toledo DSC-822e calorimeter or a Mettler-Toledo DSC30 calorimeter. Experimental 121 
conditions: aluminum crucibles of 40 μL volume or light aluminum pans of 20 μL volume, atmosphere 122 
of dry nitrogen or helium with 50 mL/min flow rate, heating rate of 10 °C/min and 100 °C/min. Both 123 
calorimeters were calibrated with indium of 99.99% purity. 124 
2.2.4. Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed on a Mettler-125 
Toledo TGA- 851e thermobalance. Experimental conditions: alumina crucibles of 70 μL volume, 126 
atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10 °C/min. 127 
 128 
  129 
3. RESULTS AND DISCUSSION 130 
 131 
3.1. Amorphous Form of AD. AD is reported to be obtained as an amorphous solid during the synthetic 132 
process,7 and many local patents describe its preparation.23−25 Therefore, we started the present work 133 
by studying the amorphous form of AD. All the attempts of preparation of the amorphous solid 134 
(lyophilization, quick evaporation, and cooling of saturated solutions) were unsuccessful, yielding 135 
mixtures of crystalline/amorphous solids. It is well recognized that amorphous phases are relatively 136 
reactive and can undergo significant changes even when stored in an inert environment.26 For example, 137 
they can absorb water very quickly when exposed to ambient conditions for a short period of time. 138 
The aforementioned problems can be circumvented by preparing the amorphous phases and 139 
characterizing them without exposure to ambient conditions. One possible approach is to prepare the 140 
amorphous phase in situ, in the sample chamber of the instrument used for its characterization. This 141 
process will provide complete control, not only over the method of preparation, but also over the 142 
subsequent storage conditions of the prepared amorphous phase. Thus, the sample history will be 143 
completely known. 144 
So, we decided to prepare the amorphous form in situ into the sample chamber of a differential scanning 145 
calorimeter (DSC) under nitrogen purge. After melting AD, the quenching from the melt resulted in the 146 
formation of the amorphous form, which was immediately characterized in the instrument without 147 
exposure to ambient environment. While amorphous phase was being heated, three thermal events were 148 
observed (Figure 2). Initial heating resulted in a change in the heat capacity at 12 °C (ΔCp= 0.963 J/gK) 149 
with no heat absorbed or evolved, attributed to a glass transition (Tg) to a supercooled liquid phase. The 150 
resulting unstable supercooled liquid crystallizes spontaneously upon heating at 71 °C. Further heating 151 
results in the melting at 78 °C of the crystalline form obtained. 152 
The stability of this amorphous phase has also been studied. Amorphous solids are characterized by the 153 
glass transition, the temperature at which they transform from a glassy state to a rubbery material. The 154 
molecular mobility increases in the rubbery state, and rapid crystallization can occur above Tg. If Tg is 155 
below room temperature, as is the case under study, the amorphous state will be metastable at room 156 
temperature, and it will be very difficult to isolate. These data explain our unsuccessful attempts of 157 
preparation of the amorphous phase, where mixtures of amorphous and crystalline forms were always 158 
obtained. On the other hand, the Tg/Tm value of 0.77 for AD falls in the typical reported 0.69−0.85 159 
range27 for most of glassy pharmaceuticals. 160 
We also characterized the amorphous form of AD by means of powder X-ray diffraction (PXRD), by 161 
preparing a sample in a 0.5 mm capillary tube under argon atmosphere, heating it upon the melting 162 
temperature, and rapidly cooling it to −65 °C. PXRD permitted us to monitor the transformation of the 163 
amorphous AD into the crystalline form as a function of time. The PXRD pattern of this sample 164 
recorded at room temperature reveals the diffuse halos characteristic of amorphous phases. Different 165 
PXRD patterns were collected periodically (Figure 3), and after some hours peaks due to crystalline AD 166 
progressively increased. 167 
Crystallization appeared to be completed in some days. Interestingly, the crystalline form observed after 168 
2 days (form II) also transformed completely into a different polymorph (form I) after 12 days. Hence, 169 
PXRD analysis led to the conclusion that amorphous AD obtained in situ after quenching the melt 170 
transforms into a metaestable form II, which eventually transforms into the most stable form I, 171 
according to the Ostwald’s so-called “Rule of Stages”.28 On the other hand, it was also observed that 172 
amorphous AD transformed into the known dihydrate when exposed to air atmosphere. 173 
All these data demonstrate that amorphous AD is not suitable for solid formulations due to its low 174 
stability at room temperature. However, if the time scale of devitrification was large (several years), then 175 
recrystallization from the amorphous state could be considered irrelevant. In this sense, the glass 176 
transition temperature is a key parameter that indicates a borderline between high and low molecular 177 
mobility of a drug, and it has been shown that the molecular mobility becomes insignificant with respect 178 
to the shelf life stability at 50 K below Tg.29 Amorphous drugs having a low Tg value can benefit from 179 
protection from recrystallization using an antiplasticizing agent to increase the Tg. Therefore, 180 
crystallization of the amorphous can be inhibited by increasing the glass transition temperature of a solid 181 
dispersion by the addition of a polymer excipient with a high Tg. 30 This stabilization can be due not 182 
only to the antiplasticizing effect of the polymer but also to the intermolecular interactions between drug 183 
and polymer. The antiplasticizing effect of the polymer on drugs in solid dispersions has been studied 184 
for some active pharmaceutical ingredients, by analyzing the Tg variation as a function of the polymer 185 
concentration.31 The Gordon−Taylor32 eq 1 for binary mixtures allows predicting the Tg value. 186 
 187 
𝑇 =  
 
  
  (1) 188 
 189 
where w1 and w2 are the weight fractions of the drug and the polymer respectively, and Tg1 and Tg2 190 
are the glass transition temperatures of both components. K can be calculated through eq 2, where ρ1 is 191 
the density of the amorphous drug and ρ2 is the density of the polymer. 192 
 193 
K = ρ1Tg1/ρ2Tg2  (2) 194 
 195 
In the present case, we explored the possibility of stabilizing the amorphous AD by preparing a solid 196 
dispersion with Copovidone as the antiplasticizing polymer. Copovidone is a 60:40 linear random 197 
copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate with a reported Tg value of 105 °C.33 Therefore, 198 
some dioxane solutions of AD and copovidone in different proportions (AD/copovidone 1:1, 1:3, 2:1, 199 
and 3:1 in weight) were frozen to −40 °C and lyophilized. Amorphous solids were obtained from 1:1 200 
and 1:3 solid dispersions, whereas mixtures of form II and amorphous were obtained from 2:1 and 3:1 201 
solid dispersions (Figure 4). 202 
The 1:1 solid dispersion was not stable at r.t. as partial crystallization to form II was observed after 1 203 
week. Therefore, the selected candidate was the 1:3 AD/copovidone solid dispersion which showed a 204 
glass transition value of 71 °C when analyzed by DSC (Figure 5), which is lower than the predicted Tg 205 
value of 96 °C by the Gordon−Taylor model. 206 
The stability of the 1:3 solid dispersion was studied under different storage conditions. The solid 207 
dispersion remained in the amorphous state at least for three months at 5 °C, r.t and 50 °C. Some 208 
crystallization traces of form I and AD dehydrate were observed after 1 week at 75% RH. These  209 
observations confirm that crystallization of AD is effectively inhibited by the combination with 210 
copovidone, being the 1:3 AD/copovidone the most stable combination. However, this solid dispersion 211 
should be kept under anhydrous conditions in order to prevent its crystallization. 212 
3.2. Solid Forms Screening. Bearing in mind the two forms identified when studying the stability of the 213 
amorphous phase, we conducted a polymorph screening of AD in order to obtain and characterize as 214 
many forms as possible. Using a broad set of thermodynamic and kinetic crystallization conditions from 215 
a variety of solvents, we were able to isolate five different anhydrous crystalline forms (I, II, III, IV, and 216 
V), the dihydrate, the methanol solvate, and the ethylenglycol and MEK hemisolvates. A summary of all 217 
experimental conditions can be found in Supporting Information. All forms were characterized by 218 
means of PXRD, DSC, and TGA. Among all these solid forms, polymorphs IV and V and ethylenglycol 219 
and MEK hemisolvates were not previously reported, whereas form I corresponds to the form 1 reported 220 
by Gilead Sciences,8 form II had been previously reported in CN101054393,9 and form III corresponds 221 
to the crystal form reported in US2006025384.10 Regarding the solvates, the dihydrate and the 222 
methanol solvate correspond to forms 2 and 3, respectively, reported by Gilead Sciences.8 223 
The powder X-ray diffractograms of the different anhydrous forms and the solvates are shown in 224 
Figures 6 and 7 respectively, while Figure 8 shows the DSC of the different anhydrous forms. TGA 225 
analysis of these forms shows no weight loss from r.t. to 150 °C (data not shown). 226 
It is of practical interest to know the relative thermodynamic stability of the anhydrous forms, and the 227 
main questions to solve are (i) to determine the most stable form at r.t. and (ii) whether two polymorphs 228 
are monotropically (one form is more stable than the other at any temperature) or enantiotropically (a 229 
transition temperature exists, below and above which the stability order is reversed) related, and for an 230 
enantiotropic system, where the transition temperature lies. Thermal analysis provides information about 231 
the melting temperature and the enthalpy of fusion of each form, which can be useful in defining the 232 
relative stability among all the forms. According to the Heat of Fusion Rule by Burger and 233 
Ramberger,34 forms I and II are monotropically related since the highest melting form I has the highest 234 
enthalpy of fusion. Thus, form I is thermodynamically more stable than form II at all temperatures up to 235 
the melting point. This fact is in agreement with the mentioned observation that amorphous AD 236 
transforms into form II which finally transforms into form I. 237 
However, as can be seen in Figure 8, forms III, IV, and V do not show a single melting endotherm but 238 
additional phenomena such as crystallization from the melt and subsequent melting. In order to prevent 239 
these additional phenomena, DSC analysis were performed at high heating rate (100 °C/min), under 240 
helium atmosphere and using light aluminum pans to improve resolution. Table 1 summarizes the 241 
physicochemical data obtained for the anhydrous modifications of AD. 242 
Regarding the stability among all anhydrous forms, although some of the polymorphs show very similar 243 
melting points, it can be suggested that all forms are monotropically related (since in each pair of forms 244 
the highest melting form has always the highest enthalpy) and with the following order of stability: form 245 
I > form III > form V > form IV > form II. 246 
Commonly, the most stable polymorphic modification is used in a marketed formulation because any 247 
other polymorphs are metastable and may therefore transform into the most stable form. Overlooking 248 
the most stable polymorph may cause failure of a marketed product because a phase transformation 249 
during storage can occur. A late-appearing stable polymorph can have a great impact on development 250 
timelines35 as has been shown by many reviews written on disappearing polymorphs.36 However, 251 
metastable forms may survive years if a high activation energy barrier has to be overcome in moving 252 
from the metastable form to the stable one. In the present case, some information about the stability of 253 
the different anhydrous forms of AD has been obtained under three different conditions: r.t., 50 °C and 254 
r.t./75% RH. Form I has shown to be stable after one month of storage at r.t. and after 1 week of storage 255 
at 50 °C. However, when leaving form I 1 week in a desiccator at 75% RH, it transforms partially to the 256 
dihydrate. Forms II and IV have resulted to be stable after 1 month at r.t, but they transform to form I at 257 
50 °C and to the dihydrate if they are exposed to 75% relative humidity conditions. Form III is stable 258 
after at least 2 weeks at r.t. and form V has shown to be stable at r.t. after one month but it transforms 259 
also to the dihydrate at r.t./75% RH. 260 
3.3. Crystal Structures Analysis. 3.3.1. Form I of Adefovir Dipivoxil. Attempts to grow quality 261 
crystals of AD form I were unsuccessful. Thus, the resolution of its crystal structure was attempted 262 
using the direct space methodology. The indexation of its monoclinic Cc cell was performed using 263 
Dicvol04.37 The final refined cell parameters are a = 13.1287(1) Å, b = 24.6784(3) Å, c = 8.34752(8) Å, 264 
β = 100.6575(5)°; V = 2657.90(5) Å3, Z = 4 with one molecule in the asymmetric unit. The crystal 265 
structure was solved by means of direct space methods using the program FOX38 with the parallel 266 
tempering algorithm. In order to accelerate the process during the parallel tempering calculation, the 267 
powder pattern was truncated to 2θ = 35° (CuKα1). The starting model of 1 was previously optimized 268 
with the commercial program SPARTAN, and some constraints were introduced to FOX, considering 269 
aromatic rings as rigid groups. Several trials of 20 million runs were performed. Subsequently the 270 
structure was refined by the Rietveld method with FullProf.39 Figure 9 depicts the final Rietveld plot. 271 
Form I crystallizes with one molecule of AD in the asymmetric unit (Figure 10) forming ribbons linked 272 
through hydrogen-bonded adenine moieties. Both Watson−Crick and Hoogsteen modes of interaction 273 
between adenine units are involved in the hydrogen-bonding assembly (Figure 12). The ribbon 274 
arrangement has been observed commonly in nucleobase pairs; however, ribbons formed only by 275 
adenine molecules were only observed for the first time in an adenine/ metal carboxylate complex40 and 276 
a similar ribbon motif has been observed in the structure of 9-methyladenine.41 277 
3.3.2. Isostructural Solvates. Three solvates have been identified and their crystal structures were solved 278 
by means of single crystal X-ray diffraction. The three solvates constitute a family of isostructural 279 
solvates with the solvent molecules (MeOH, ethylenglycol, and MEK) residing in similar regions of the 280 
crystal structure. This phenomenon has been observed previously for a variety of pharmaceutical 281 
compounds such as Finasteride,42 Tenofovir disoproxyl fumarate,43 olanzapine,44 and Nevirapine.45 282 
The three triclinic structures crystallize in the P1̅space group with very similar unit cell parameters 283 
(Table 2). Figure 11 displays the overlapped asymmetric unit for the three solvates. In the MEK and 284 
ethylenglycol hemisolvates, the solvent molecules are disordered around an inversion center. 285 
The main intermolecular interactions are common; Hoogsteen pairing of adenine moieties in 286 
combination with strong PO···HN contacts which form the backbone of the crystal structure are 287 
reinforced by weaker secondary interactions as shown in Figure 12. In the case of the methanol and 288 
ethylenglycol solvates, the solvent molecule establishes a strong hydrogen bond with the pyperidine 289 
nitrogen, while in the MEK hemisolvate although the solvent molecule occupy the same position, only 290 
weak CO···HC contacts are formed. On the other side, the previously published dihydrate structure11 291 
presents the same Hoogsteen pairing motif, while water molecules establish hydrogen bonds with the 292 
pyperidine nitrogen and the NH2 group of the adenine moiety. However, it is not isostructural to the 293 
three solvates presented in this work. 294 
Finally, some cocrystal forms with carboxylic acids have been reported and crystal structures with the 295 
succinic46 and suberic acids47 have been solved. The succinic acid cocrystal (the only one available at 296 
the CCDC) shows complementary hydrogen bonded assemblies of adenine/carboxylic acid interactions 297 
which break the adenine self-assembling motif. This R2 2(9) heterosynthon is evidence of hydrogen 298 
bonding in the Hoogsteen mode.48 299 
  300 
4. CONCLUSION 301 
 302 
The present study focused on extending the solid state landscape of the important prodrug Adefovir 303 
dipivoxil. Two new polymorphs and two new solvates of Adefovir dipivoxil have been identified during 304 
an intensive solid forms screening. The stability of the amorphous phase has been studied, and the use of 305 
copovidone as antiplasticizing agent has shown to inhibit its crystallization under anhydrous conditions. 306 
Moreover, the interconversion among all the known crystal forms has been investigated, being the most 307 
stable form I monotropically related with the rest of the anhydrous forms. The elusive crystal structure 308 
of form I has been determined by means of direct space methods, while the crystal structures of three 309 
solvates have been solved from single crystal X-ray diffraction. Data have shown that these solvates are 310 
metrically isostructural (very similar unit cell and the same space group), and the analysis of the crystal 311 
structures revealed important differences in the intermolecular interactions with respect to those in form 312 
I. 313 
 314 
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.400 
Legends to figures 401 
 402 
Figure 1 Zafirlukast (ZF). 403 
 404 
Figure 2. PXRD of the new solvates and anhydrous form of ZF. 405 
 406 
Figure 3 DSC and TGA of the ZF ACN solvate. DSC curve of the anhydrous form is shown for 407 
comparison. 408 
 409 
Fig. 4 DSC and TGA of the ZF BuOH solvate. DSC curve of the anhydrous form is shown for 410 
comparison. 411 
 412 
Figure 5. Ribbons of self-assembled molecules of ZF in Form X. 413 
 414 
Figure 6. (a) Cmethoxy−H···π interaction and (b) Carene−H···π interaction in Form X of ZF. 415 
 416 
Figure 7. Self-assembled dimers of ZF stabilized by peripheral acetonitrile−amide interactions in ZF 417 
acetonitrile solvate (some hydrogens have been omitted for clarity). 418 
 419 
Figure 8. Hydrogen bond interactions established between butanol and ZF molecules in the butanol 420 
solvate. 421 
 422 
Figure 9. Chains of hydrogen-bonded molecules of ZF in the butanol solvate. 423 
 424 
Figure 10. CH···π interactions observed in the butanol solvate. 425 
 426 
Figure 11. Chains of ZF molecules in the piperazine cocrystal. 427 
 428 
Figure 12. Cavity occupied by the piperazine molecule in the cocrystal (hydrogens and fragments of the 429 
ZF molecules have been omitted for clarity). 430 
 431 
Figure 13. PXRD patterns of the five ZF/piperazine cocrystals. 432 
 433 
Figure 14. PXRD patterns of the two 2:1 ZF/piperazine cocrystals. 434 
 435 
Figure 15. Le Bail fit of 2:1 ZF/piperazine cocrystal Form B. 436 
Figure 16. DSC and TGA traces of the 1:1 cocrystal Form C. 437 
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